Non-small cell lung cancer
Not yet recruitingStudy of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors
Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors
- Disease:Non-small cell lung cancer
- Substances:AtezolizumabCemiplimab+4
Germany- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Immunitybio Inc.














